Tirzepatide

A medicine that acts on GIP and GLP-1 receptors. These are two body signal receivers linked to food and blood sugar.

Sources for this tile

• SURMOUNT-1: tirzepatide and obesity (Jastreboff and colleagues · 2022 · Published abstract · checked 2026-10-08)

The shared reference is SURMOUNT-1. Its results are from a trial product in adults with obesity, not proof of the contents of a supplier vial.

Sources for this tile

• SURMOUNT-1: tirzepatide and obesity (Jastreboff and colleagues · 2022 · Published abstract · checked 2026-10-08)

Open the pathway notes below. A biological pathway is a possible chain of events in the body. The grade states where it was tested.

Sources for this tile

• SURMOUNT-1: tirzepatide and obesity (Jastreboff and colleagues · 2022 · Published abstract · checked 2026-10-08)

Each proposed mechanism

Two signal receivers

The trial describes GIP and GLP-1 receptor activity. This is different from a peptide studied for tissue repair.

Evidence note: Described biology; not directly tested by this outcome trial

Sources

• SURMOUNT-1: tirzepatide and obesity (Jastreboff and colleagues · 2022 · Published abstract · checked 2026-10-08)

Go deeper

Two signal receivers Described biology; not directly tested by this outcome trial

The trial describes GIP and GLP-1 receptor activity. This is different from a peptide studied for tissue repair.

Sources

• SURMOUNT-1: tirzepatide and obesity (Jastreboff and colleagues · 2022 · Published abstract · checked 2026-10-08)

Open the outcome notes. They show the tested condition and what was measured. A positive marker, a mouse result and a clinical benefit are different things.

Sources for this tile

• SURMOUNT-1: tirzepatide and obesity (Jastreboff and colleagues · 2022 · Published abstract · checked 2026-10-08)

Read this before you read a benefit into it

Laboratory and animal results describe what happened in that model. They are not proven healing in a person. Human studies name their own population, outcome and limits. Both are kept apart here on purpose.

Human research found for this product

SURMOUNT-1: tirzepatide and obesity A

Proof grade	A
Design	Randomised placebo-controlled phase 3
People or model	Adults with obesity or overweight and a weight-related condition; diabetes excluded
Number	2539
Outcome measured	Body weight
Result	At 72 weeks, mean weight change was -15.0%, -19.5% and -20.9% in the three active groups, versus -3.1% with placebo.
Route in the study	Subcutaneous
Duration	72 weeks
Risks noted	Gut symptoms were common; some participants stopped treatment.
Regimen seen in the study	Trial maintenance groups: 5, 10 or 15 mg weekly after escalation; research observation only.
Personal regimen	Not set. A study regimen is not a personal instruction.

Source

• SURMOUNT-1: tirzepatide and obesity (Jastreboff and colleagues · 2022 · Published abstract · checked 2026-10-08)

Go deeper

Body weight A

A: Tested in Adults with obesity or overweight and a weight-related condition; diabetes excluded. Read the study result in the human or researcher layer. This is a tested outcome, not a promised benefit.

Sources

• SURMOUNT-1: tirzepatide and obesity (Jastreboff and colleagues · 2022 · Published abstract · checked 2026-10-08)

Each claim keeps its own source, evidence grade and limits. This is a scoped first research edition. It is not a full review or a personal treatment plan.

Sources for this tile

• SURMOUNT-1: tirzepatide and obesity (Jastreboff and colleagues · 2022 · Published abstract · checked 2026-10-08)

Overall state of the evidence

Status: scoped-human-evidence

These averages do not predict one person's result. The supplier product, health history and current product label have not been checked.

Risk summary

These averages do not predict one person's result. The supplier product, health history and current product label have not been checked.

Unwanted effects reported in the sources

• Gut symptoms were common; some participants stopped treatment. (SURMOUNT-1: tirzepatide and obesity)

What is still open

• Supplier identity and batch match have not been verified
• Full-text systematic review and complete interactions are not finished
• Exact product and current label
• Diabetes medicines and low blood sugar history
• Prior gut problems, allergies and pregnancy status

Checks a reviewer must finish first

• Exact product and current label
• Diabetes medicines and low blood sugar history
• Prior gut problems, allergies and pregnancy status

How to read the proof grades

• A: Controlled human trial. Note whether randomisation and blinding were confirmed.
• B: Small uncontrolled human study or chart review.
• C: Whole-animal intervention.
• D: Cell or other laboratory study.
• E: User reports. Kept separate and never substituted for a measured outcome.
• ungraded: Identity sources, official labels, notices, reviews and unverified claims are not assigned an efficacy grade.

Go deeper

How to read the proof Open the checked detail

A: controlled human trial. State whether it was blinded and randomized. B: small uncontrolled human study or chart review; a weak clinical comparison is marked with its design limits. C: whole-animal work. D: cells or other lab work. E: user reports.

A grade describes the kind of evidence for one claim. It does not grade every claim about a peptide or approve a product. Labels, history and regulatory reviews are named sources, not efficacy grades.

Sources

• Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)

Open questions Open the checked detail

Supplier identity and batch match have not been verified

Full-text systematic review and complete interactions are not finished

Exact product and current label

Diabetes medicines and low blood sugar history

Prior gut problems, allergies and pregnancy status

Open the linked human study records. Each names the tested group, design, result and limits. Related-compound and non-treatment studies are marked so they cannot be used as product treatment proof.

Sources for this tile

• SURMOUNT-1: tirzepatide and obesity (Jastreboff and colleagues · 2022 · Published abstract · checked 2026-10-08)

Studies named in this tile

Personal regimen	Not set. A study regimen is not a personal instruction.

What people report

No user reports are recorded for this product. The library keeps human studies and user reports in separate places, so nothing is filled in here.

Each human record

SURMOUNT-1: tirzepatide and obesity A

Proof grade	A
Design	Randomised placebo-controlled phase 3
People or model	Adults with obesity or overweight and a weight-related condition; diabetes excluded
Number	2539
Outcome measured	Body weight
Result	At 72 weeks, mean weight change was -15.0%, -19.5% and -20.9% in the three active groups, versus -3.1% with placebo.
Route in the study	Subcutaneous
Duration	72 weeks
Risks noted	Gut symptoms were common; some participants stopped treatment.
Regimen seen in the study	Trial maintenance groups: 5, 10 or 15 mg weekly after escalation; research observation only.
Personal regimen	Not set. A study regimen is not a personal instruction.

Source

• SURMOUNT-1: tirzepatide and obesity (Jastreboff and colleagues · 2022 · Published abstract · checked 2026-10-08)

This is the shared library. No client has been assessed in this record. This tile will use the person's own words, a named target and checked rule-outs after intake. A catalog entry does not mean it is suitable for someone.

These averages do not predict one person's result. The supplier product, health history and current product label have not been checked.

Sources for this tile

• SURMOUNT-1: tirzepatide and obesity (Jastreboff and colleagues · 2022 · Published abstract · checked 2026-10-08)

The trial used injections under the skin. It does not give a schedule for a DNC client. Research routes describe what was studied. They are not a client administration guide.

Sources for this tile

• SURMOUNT-1: tirzepatide and obesity (Jastreboff and colleagues · 2022 · Published abstract · checked 2026-10-08)

Routes seen in the research

• Subcutaneous

Dose and cycle fields in the library

These are blank on purpose. A personal amount, schedule, mixing or storage instruction is only written into an agreed plan after a reviewer checks the exact product.